Top Message

Established in Kagoshima in 1957 as Japan's first contract research organization (CRO), SNBL has built a unique business model centered on life sciences related to drug development with the mission of "supporting the improvement of drug discovery and medical technology and freeing humanity from suffering."

Since our founding, we have built a solid business foundation in the contract non-clinical testing business, expanded our business into the contract clinical trial field in '91, and established the Translational Research (TR) business unit in '97 to develop basic drug discovery technologies that will serve as the upstream area of drug development. Then, in 2005, we launched the Medipolis business, which balances not only economic benefits but also social benefits from the perspective of ESG/SDGs.

Currently, as a CRO, I am developing a support business that quickly delivers better drugs and medical care to patients in all new drug discovery modalities, and as part of my TR business, I am actively working on a new business that supports the management of excellent bio-ventures that share our aspirations, and several bio-ventures have been listed on stock exchanges in Japan and overseas. By co-developing or licensing out these successful bio-ventures with major pharmaceutical companies, we have accumulated a track record of supporting new drug development that other CROs cannot do.

Under the slogan of "I'm happy, you're happy, and everyone is happy," we will work to improve our corporate value. We sincerely ask for your continued support and encouragement.

SNBL Co., Ltd.

Chairman and CEO